<DOC>
	<DOCNO>NCT01993173</DOCNO>
	<brief_summary>The aim study assess immunogenicity safety profile ADACEL compare local adsorb diphtheria tetanus combine vaccine ( local DT local Td vaccine participant China . Primary objective : - To describe diphtheria tetanus seroprotection rate pertussis booster response rate induce study vaccine : ADACEL vaccine ( study age group ) , local DT vaccine ( child ) , local Td vaccine ( adolescent adult ) . Secondary Objectives : - To describe group immunogenicity study vaccine baseline 1 month vaccination . - To describe safety study vaccine</brief_summary>
	<brief_title>Sanofi Pasteur 's Tdap Combined Vaccine Booster Versus Local DT Vaccine Children Versus Local Td Vaccine Adolescents Adults China .</brief_title>
	<detailed_description>Study participant receive single booster dose ADACEL ( Tdap vaccine ) single booster dose local DT local Td vaccine , depend age subgroup . Immunogenicity assess 28 day post-vaccination ; safety profile assessed subject Day 35 post vaccination .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 4 64 year day inclusion For child adolescent ( 4 17 year ) : Informed consent form sign dated parent ( ) another legally acceptable representative assent form sign date subject age 8 17 year For adult ( 18 year ) : Informed consent form sign date subject Subject parent / legally acceptable representative ( subject 17 year ) able attend schedule visit comply trial procedure According China National Immunization Recommendations , write documentation complete primary series fourth dose diphtheria , tetanus , pertussis ( DTP ) vaccine subject age 4 7 year write documentation oral confirmation complete primary series fourth dose DTP vaccine subject age 8 64 year Participation time study enrollment ( 4 week precede first trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure . Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 4 week follow trial vaccination . Previous vaccination diphtheria tetanus disease either trial vaccine another vaccine ( except Tetanusprone wind management adult ) past 12 month . Previous fifth vaccination pertussis disease . Receipt immune globulin , blood bloodderived product past 3 month . Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy . Known ( laboratoryconfirmed / selfreported ) Human Immunodeficiency Virus ( HIV ) Hepatitis C seropositivity . History diphtheria , tetanus , pertussis infection ( confirm either clinically , serologically microbiologically ) . Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance . Laboratoryconfirmed / selfreported thrombocytopenia , contraindicate intramuscular vaccination . Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Chronic illness , opinion investigator , stage might interfere trial conduct completion . Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 37.1°C ) . A prospective subject include study condition resolve febrile event subside . History contraindication vaccination pertussis contain vaccine , include : Encephalopathy ( e.g , coma , decrease level consciousness , prolonged seizure ) within 7 day previous dose pertussis contain vaccine attributable another identifiable cause Progressive neurologic disorder , include infantile spasm , uncontrolled epilepsy , progressive encephalopathy Axillary temperature &gt; 39.4°C within 48 hour attributable another identifiable cause Collapse shocklike state ( hypotonichyporesponsive episode ) within 48 hour . Prior personal history GuillainBarré syndrome . Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>ADACEL®</keyword>
	<keyword>Tdap vaccine</keyword>
</DOC>